I
Irini Kantopoulos
Biotech Analyst and Portfolio Manager at Fidelity Investments, managing the Fidelity Advisor Biotechnology Fund
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Aug 11, 2026
08.11.26 - Is it too late to invest in Biotech stocks?
H
8:07Heather HegedusHOST
what has been happening with biotech stocks? What is driving this most recent surge right now?
I
8:11Irini KantopoulosGUEST
Well, so in 2021, biotech was really the savior, right? It allowed all of us to get our COVID vaccines and rejoin humanity.
I
8:19Irini KantopoulosGUEST
And so generalists were like, what is this biotech? Everything seems to work.
I
8:22Irini KantopoulosGUEST
If we can go from nothing to a COVID vaccine in under 12 months, that's amazing.
H
13:31Heather HegedusHOST
But I'm wondering from you, are we just in the infancy stages of this or have we not even started yet? You know, where are we in the timeline of AI impacting drug development and, you know, cures for all different kinds of diseases?